CN109793761A - 一种用于增强t细胞免疫功能的组合物及其制备方法 - Google Patents
一种用于增强t细胞免疫功能的组合物及其制备方法 Download PDFInfo
- Publication number
- CN109793761A CN109793761A CN201711144522.9A CN201711144522A CN109793761A CN 109793761 A CN109793761 A CN 109793761A CN 201711144522 A CN201711144522 A CN 201711144522A CN 109793761 A CN109793761 A CN 109793761A
- Authority
- CN
- China
- Prior art keywords
- bacteroides fragilis
- cancer
- composition
- inactivation
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 230000036737 immune function Effects 0.000 title claims abstract description 19
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims description 10
- 241000606124 Bacteroides fragilis Species 0.000 claims abstract description 104
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 40
- 230000002779 inactivation Effects 0.000 claims description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 241000894006 Bacteria Species 0.000 claims description 14
- 201000001441 melanoma Diseases 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 8
- 230000006798 recombination Effects 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 5
- 230000004151 fermentation Effects 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 235000013373 food additive Nutrition 0.000 claims description 5
- 239000002778 food additive Substances 0.000 claims description 5
- 238000012239 gene modification Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000009466 transformation Effects 0.000 claims description 5
- 239000008236 heating water Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 238000011426 transformation method Methods 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims description 2
- 239000012228 culture supernatant Substances 0.000 claims 2
- 238000009630 liquid culture Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 25
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 230000000694 effects Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000002504 physiological saline solution Substances 0.000 description 11
- 230000002265 prevention Effects 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000000118 anti-neoplastic effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000606125 Bacteroides Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 101150046249 Havcr2 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 241000682973 Quasibacillus Species 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (13)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711144522.9A CN109793761B (zh) | 2017-11-17 | 2017-11-17 | 一种用于增强t细胞免疫功能的组合物及其制备方法 |
KR1020207014957A KR20200071123A (ko) | 2017-11-17 | 2017-12-26 | T세포의 면역기능 강화를 위한 조성물 및 그의 제조방법 |
PCT/CN2017/118590 WO2019095508A1 (zh) | 2017-11-17 | 2017-12-26 | 一种用于增强t细胞免疫功能的组合物及其制备方法 |
AU2017440014A AU2017440014A1 (en) | 2017-11-17 | 2017-12-26 | Compositions for enhancing immune function of t cells and preparation methods therefor |
US16/764,413 US20200353014A1 (en) | 2017-11-17 | 2017-12-26 | Compositions for enhancing immune function of t cells and preparation methods therefor |
CA3082716A CA3082716A1 (en) | 2017-11-17 | 2017-12-26 | Compositions for enhancing immune function of t cells and preparation methods therefor |
JP2020545408A JP2021503504A (ja) | 2017-11-17 | 2017-12-26 | T細胞の免疫機能を増強するための組成物及びその製造方法 |
EP17932406.6A EP3712246A4 (en) | 2017-11-17 | 2017-12-26 | COMPOSITION FOR INCREASING THE IMMUNE FUNCTION OF T-CELLS AND MANUFACTURING METHOD FOR IT |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711144522.9A CN109793761B (zh) | 2017-11-17 | 2017-11-17 | 一种用于增强t细胞免疫功能的组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109793761A true CN109793761A (zh) | 2019-05-24 |
CN109793761B CN109793761B (zh) | 2021-03-05 |
Family
ID=66538461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711144522.9A Ceased CN109793761B (zh) | 2017-11-17 | 2017-11-17 | 一种用于增强t细胞免疫功能的组合物及其制备方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20200353014A1 (zh) |
EP (1) | EP3712246A4 (zh) |
JP (1) | JP2021503504A (zh) |
KR (1) | KR20200071123A (zh) |
CN (1) | CN109793761B (zh) |
AU (1) | AU2017440014A1 (zh) |
CA (1) | CA3082716A1 (zh) |
WO (1) | WO2019095508A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109200063A (zh) * | 2017-06-29 | 2019-01-15 | 中山大学 | 脆弱拟杆菌在制备用于治疗和预防结核病的药物中的应用 |
CN114306616A (zh) * | 2022-01-12 | 2022-04-12 | 广州知易生物科技有限公司 | 脆弱拟杆菌和免疫检查点抑制剂的新应用 |
CN114344338A (zh) * | 2022-01-12 | 2022-04-15 | 广州知易生物科技有限公司 | 脆弱拟杆菌和/或其两性离子荚膜多糖的新应用 |
CN114469987A (zh) * | 2022-01-12 | 2022-05-13 | 广州知易生物科技有限公司 | 脆弱拟杆菌两性离子荚膜多糖与免疫检查点抑制剂联合用药治疗生殖泌尿系统肿瘤的应用 |
CN114344325B (zh) * | 2022-01-12 | 2023-07-14 | 广州知易生物科技有限公司 | 脆弱拟杆菌及其两性离子荚膜多糖在制备用于防治生殖泌尿系统肿瘤的药物中的应用 |
WO2023134195A1 (zh) * | 2022-01-12 | 2023-07-20 | 广州知易生物科技有限公司 | 脆弱拟杆菌联合免疫检查点抑制剂在治疗皮肤肿瘤中的应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110496140B (zh) * | 2018-05-18 | 2022-05-31 | 瑞微(深圳)生物科技有限公司 | 脆弱拟杆菌或阿克曼粘细菌在制备用于预防或治疗肿瘤的药物中的应用 |
CN114344340B (zh) * | 2022-01-12 | 2023-07-25 | 广州知易生物科技有限公司 | 脆弱拟杆菌与pd-1及pd-l1抗体联合用药治疗呼吸系统肿瘤中的应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101022826A (zh) * | 2004-06-07 | 2007-08-22 | 哈罗尔·戴维·贡 | 用于癌症治疗的细菌组合物 |
CN102947441A (zh) * | 2010-06-01 | 2013-02-27 | 穆尔研究企业有限责任公司 | 来自拟杆菌属的细胞组分、其组合物和使用拟杆菌或其细胞组分的治疗方法 |
CN103750341A (zh) * | 2014-01-13 | 2014-04-30 | 苏州万生源生物科技有限公司 | 一种灭活拟杆菌微生态制剂及其制备方法 |
CN105434477A (zh) * | 2015-10-29 | 2016-03-30 | 广州知易生物科技有限公司 | 脆弱拟杆菌在抗水产病原菌中的应用 |
EP3012270A1 (en) * | 2014-10-23 | 2016-04-27 | Institut Gustave Roussy | Products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
US20160220646A1 (en) * | 2015-01-29 | 2016-08-04 | Oxyrase, Inc. | Methods for inhibiting tumor growth |
CN106399141A (zh) * | 2015-07-31 | 2017-02-15 | 广州知易生物科技有限公司 | 一种脆弱拟杆菌及其应用 |
CN109528775A (zh) * | 2017-09-22 | 2019-03-29 | 中山大学 | 脆弱拟杆菌在制备用于治疗和预防肿瘤的药物中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1029857C (zh) * | 1990-05-03 | 1995-09-27 | 张季阶 | 拟杆菌微生态制剂的制备方法 |
JP2016521284A (ja) * | 2013-05-10 | 2016-07-21 | カリフォルニア インスティチュート オブ テクノロジー | 大腸ガンのプロバイオティクスによる防止および処置 |
CN106727730A (zh) * | 2016-12-31 | 2017-05-31 | 健务(上海)生物科技有限公司 | 调节机体免疫力抗癌的生物菌液及其制备方法 |
-
2017
- 2017-11-17 CN CN201711144522.9A patent/CN109793761B/zh not_active Ceased
- 2017-12-26 KR KR1020207014957A patent/KR20200071123A/ko not_active Application Discontinuation
- 2017-12-26 WO PCT/CN2017/118590 patent/WO2019095508A1/zh unknown
- 2017-12-26 EP EP17932406.6A patent/EP3712246A4/en not_active Withdrawn
- 2017-12-26 AU AU2017440014A patent/AU2017440014A1/en not_active Abandoned
- 2017-12-26 US US16/764,413 patent/US20200353014A1/en not_active Abandoned
- 2017-12-26 CA CA3082716A patent/CA3082716A1/en not_active Abandoned
- 2017-12-26 JP JP2020545408A patent/JP2021503504A/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101022826A (zh) * | 2004-06-07 | 2007-08-22 | 哈罗尔·戴维·贡 | 用于癌症治疗的细菌组合物 |
CN102947441A (zh) * | 2010-06-01 | 2013-02-27 | 穆尔研究企业有限责任公司 | 来自拟杆菌属的细胞组分、其组合物和使用拟杆菌或其细胞组分的治疗方法 |
CN103750341A (zh) * | 2014-01-13 | 2014-04-30 | 苏州万生源生物科技有限公司 | 一种灭活拟杆菌微生态制剂及其制备方法 |
EP3012270A1 (en) * | 2014-10-23 | 2016-04-27 | Institut Gustave Roussy | Products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
US20160220646A1 (en) * | 2015-01-29 | 2016-08-04 | Oxyrase, Inc. | Methods for inhibiting tumor growth |
CN106399141A (zh) * | 2015-07-31 | 2017-02-15 | 广州知易生物科技有限公司 | 一种脆弱拟杆菌及其应用 |
CN105434477A (zh) * | 2015-10-29 | 2016-03-30 | 广州知易生物科技有限公司 | 脆弱拟杆菌在抗水产病原菌中的应用 |
CN109528775A (zh) * | 2017-09-22 | 2019-03-29 | 中山大学 | 脆弱拟杆菌在制备用于治疗和预防肿瘤的药物中的应用 |
Non-Patent Citations (2)
Title |
---|
JENNY L. JOHNSON等: "Polysaccharide A from the Capsule of Bacteroides fragilis Induces Clonal CD4+T Cell Expansion", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 * |
曹澍泽主编: "《兽医微生物学及免疫学技术》", 31 May 1992, 北京农业大学出版社 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109200063A (zh) * | 2017-06-29 | 2019-01-15 | 中山大学 | 脆弱拟杆菌在制备用于治疗和预防结核病的药物中的应用 |
CN114306616A (zh) * | 2022-01-12 | 2022-04-12 | 广州知易生物科技有限公司 | 脆弱拟杆菌和免疫检查点抑制剂的新应用 |
CN114344338A (zh) * | 2022-01-12 | 2022-04-15 | 广州知易生物科技有限公司 | 脆弱拟杆菌和/或其两性离子荚膜多糖的新应用 |
CN114469987A (zh) * | 2022-01-12 | 2022-05-13 | 广州知易生物科技有限公司 | 脆弱拟杆菌两性离子荚膜多糖与免疫检查点抑制剂联合用药治疗生殖泌尿系统肿瘤的应用 |
CN114344325B (zh) * | 2022-01-12 | 2023-07-14 | 广州知易生物科技有限公司 | 脆弱拟杆菌及其两性离子荚膜多糖在制备用于防治生殖泌尿系统肿瘤的药物中的应用 |
WO2023134195A1 (zh) * | 2022-01-12 | 2023-07-20 | 广州知易生物科技有限公司 | 脆弱拟杆菌联合免疫检查点抑制剂在治疗皮肤肿瘤中的应用 |
WO2023134209A1 (zh) * | 2022-01-12 | 2023-07-20 | 广州知易生物科技有限公司 | 脆弱拟杆菌和免疫检查点抑制剂的新应用 |
CN114344338B (zh) * | 2022-01-12 | 2023-08-04 | 广州知易生物科技有限公司 | 脆弱拟杆菌和/或其两性离子荚膜多糖的新应用 |
Also Published As
Publication number | Publication date |
---|---|
EP3712246A1 (en) | 2020-09-23 |
EP3712246A4 (en) | 2020-12-23 |
CN109793761B (zh) | 2021-03-05 |
CA3082716A1 (en) | 2019-05-23 |
KR20200071123A (ko) | 2020-06-18 |
JP2021503504A (ja) | 2021-02-12 |
AU2017440014A1 (en) | 2020-06-18 |
WO2019095508A1 (zh) | 2019-05-23 |
US20200353014A1 (en) | 2020-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109793761A (zh) | 一种用于增强t细胞免疫功能的组合物及其制备方法 | |
CN110496140A (zh) | 脆弱拟杆菌或阿克曼粘细菌在制备用于预防或治疗肿瘤的药物中的应用 | |
CN109528775A (zh) | 脆弱拟杆菌在制备用于治疗和预防肿瘤的药物中的应用 | |
CN110638838B (zh) | 阿克曼粘细菌或普氏菌在制备用于增强抗肿瘤免疫功能的药物中的应用 | |
CN104224851B (zh) | 动物双歧杆菌乳酸亚种CGMCC No.9273的应用 | |
CN110393800A (zh) | 增强食管鳞状细胞癌化疗敏感的药物 | |
CN106222141B (zh) | Nk细胞培养液和细胞培养方法 | |
CN105349463B (zh) | 一种假单胞菌菌株及其应用 | |
CN102727524A (zh) | 一种抗cd3/抗cd133双特异性抗体装载的cik细胞的应用 | |
CN114344342B (zh) | 副干酪乳杆菌Lp. R3在制备预防或治疗肿瘤药物中的应用 | |
CN106265760B (zh) | 戈氏梭菌驯化株在制备放疗增敏剂中的应用 | |
Fakruddin et al. | Next-Generation Probiotics-The Future of Biotherapeutics | |
CN104099279B (zh) | 一种缓解畜禽应激的复合微生态制剂及应用 | |
CN111450124A (zh) | 阿克曼粘菌或普氏菌在增加肿瘤微环境γδT细胞积累并增强抗肿瘤免疫功能药物中的应用 | |
CN108285480B (zh) | 十二肽及其在制备治疗和/或诊断宫颈癌的产品中的应用 | |
CN108285479B (zh) | 七肽及其在制备治疗和/或诊断宫颈癌的产品中的应用 | |
Aminaei et al. | Primary evidence on the potential of Lactobacillus paracasei in treatment of hepatocellular carcinoma | |
Muhammad | Shireen. Antibacterial Approach of Lactobacillus Species Isolated From Exterior of Fruits | |
Arbab Soleimani et al. | Investigating the effects of lactobacillus plantarum strain ATCC 8014 on gene expression of NF-ĸB, TLR-4, and BCL-2 in oral rat cancer induced by 4-Nitroquioline 1-Oxide | |
Teng et al. | Pasteurized Akkermansia muciniphila improves immunity and relieves other toxic effects in 5-fluorouracil treated BALB/c mice | |
CN104711214A (zh) | 一种大肠杆菌bbm2015001菌株及其用途 | |
Deng | Gut microbiota and cancer immunotherapy: mechanisms and modifications | |
Ullah et al. | Polysaccharides derived from Deglet Noor dates modulate amoxicillin-induced dysbiosis and enhance intestinal barrier function | |
Li et al. | Inhibitory Effects of Latilactobacillus curvatus BYB3 Cell-Free Extract on Human Melanoma B16F10 Cells and Tumorigenic Mice | |
WO2020223988A1 (zh) | 肠道细菌在制备用于促进TCR γδ+T细胞增殖的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190906 Address after: 518054 Donghua Garden, Nanshan Street, Nanshan District, Shenzhen City, Guangdong Province, 810 Applicant after: SHENZHEN YUEYAO LIFE TECHNOLOGY Co.,Ltd. Address before: 510275 Xingang West Road, Guangdong, China, No. 135, No. Applicant before: Sun Yat-sen University |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200728 Address after: 3009 venture capital building, No.9 Tengfei Road, huanggekeng community, Longcheng street, Longgang District, Shenzhen City, Guangdong Province Applicant after: Ruiwei (Shenzhen) Biotechnology Co.,Ltd. Address before: 518054 Donghua Garden, Nanshan Street, Nanshan District, Shenzhen City, Guangdong Province, 810 Applicant before: SHENZHEN YUEYAO LIFE TECHNOLOGY Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
IW01 | Full invalidation of patent right | ||
IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20230104 Decision number of declaring invalidation: 59845 Granted publication date: 20210305 |